Side-by-side · Research reference

CortagenvsIGF-DES

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/35 cited

BAnimal-StrongHUMAN-REVIEWED8/60 cited

Cortagen

Bioregulatory Tetrapeptide · Khavinson-School

TetrapeptideStructure

↓ LPO productsAntioxidant effectKozina 2007

AnimalEvidence level

Injectable · Animal models

IGF-DES

IGF-1 Analogue · Truncated N-Terminal

~10×Potency vs IGF-1

ReducedIGFBP binding

ResearchStatus

Injection (local or systemic) · Research protocols onlyBredehöft 2008

01Mechanism of Action

Parameter

Cortagen

IGF-DES

Primary target

Cerebral cortex tissue — molecular targets under investigation

IGF-1 receptor (IGF1R)Shields 2007

Pathway

Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007

IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation

Downstream effect

Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007 Anisimov 2004

Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation

Feedback intact?

—

Unknown — no human endocrine feedback data

Origin

Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004

Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008

Antibody development

—

02Dosage Protocols

Parameter

Cortagen

IGF-DES

Animal model dose (rat)

Injection protocol (dose not specified in abstracts)

Multiple injections over study period.

—

Avian model dose (chicken)

40-day injection courseKuznik 2008

Compared to epithalon in hypophysectomized and aged birds.

—

Human peripheral nerve study

Therapeutic course (protocol details not provided)

Posttraumatic recovery context — reference cited but not detailed.

—

Evidence basis

Animal mechanistic studies

Animal models + in vitro only

Route

Injectable (inferred from animal protocols)

Subcutaneous or intramuscular (local injection favored)

Local delivery maximizes tissue-specific uptake.

Research dose range

—

10–100 ng/mL (in vitro); μg doses (animal models)

Highly context-dependent; no standardized human protocol.

Frequency

—

Variable — daily to multiple times daily in research

Human data

—

None — no clinical trials

Half-life

—

Shorter than IGF-1 due to reduced IGFBP binding

Rapid tissue uptake, limited systemic circulation.

03Metabolic / Fat Loss Evidence

Parameter

Cortagen

IGF-DES

Primary mechanism

—

Indirect via muscle hypertrophy → metabolic rate elevation

Direct lipolysis

—

Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic

Prostate model

—

Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002

Context-specific anti-proliferative effect, not fat loss.

04Side Effects & Safety

Parameter

Cortagen

IGF-DES

Antioxidant suppression

Suppression of antioxidant activity noted alongside LPO reductionKozina 2007

Mechanism unclear — possible homeostatic adaptation.

—

Immune/hemostasis effects

No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008

Epithalon reversed deficits; cortagen did not.

—

Human safety data

No adverse events reported in peripheral nerve recovery context

Limited detail in available abstracts.

Absent — no human trials, all effects theoretical or extrapolated

Hypoglycemia risk

—

Theoretical — IGF-1 axis enhances glucose uptake

Mitogenic risk

—

Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002

Injection site reaction

—

Expected — erythema, irritation, local swelling

Edema / Fluid retention

—

Possible via sodium retention (IGF-1 axis effect)

Unknown long-term effects

—

No chronic dosing studies in humans; endocrine, metabolic consequences unknown

Absolute Contraindications

Cortagen

—

IGF-DES

·Active malignancy or history of cancer (mitogenic risk)
·Pregnancy / lactation (no safety data)
·Hypoglycemia disorders

Relative Contraindications

Cortagen

—

IGF-DES

·Diabetes mellitus (unpredictable glucose effects)
·Renal or hepatic impairment (clearance unknown)
·Edema-prone conditions (heart failure, nephrotic syndrome)

05Administration Protocol

Parameter

Cortagen

IGF-DES

1. Preparation

Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.

Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.

2. Injection site

Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.

Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.

3. Timing

Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.

Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.

4. Storage

Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.

Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.

5. Needle gauge

—

27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.

6. Monitoring

—

Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.

06Stack Synergy

Cortagen

— no documented stacks

IGF-DES

+ BPC-157

Moderate

View BPC-157 →

Des(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.

Des(1-3)IGF-1: Research dose post-workout (local IM)
BPC-157: 250–500 mcg SQ, daily or twice daily
Frequency: Daily or per research protocol
Primary benefit: Accelerated muscle repair, enhanced hypertrophy, connective tissue support

+ TB-500

Moderate

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.

Des(1-3)IGF-1: Research dose post-workout (local IM)
TB-500: 2–5 mg SQ, 2× weekly
Frequency: Per research cycle
Primary benefit: Muscle hypertrophy, injury recovery, vascular support